PGP and cancer: Relevantly, in vitro studies also revealed a potential enhancement of cytotoxicity in cancer cells resistant to doxorubicin and vincristine derived from trabectedin’s ability to downregulate P-gp, which showed its usefulness in combination with other chemotherapeutic agents that are P-gp substrates [112].